MX2023004109A - Administracion selectiva de oligonucleótidos a células gliales. - Google Patents

Administracion selectiva de oligonucleótidos a células gliales.

Info

Publication number
MX2023004109A
MX2023004109A MX2023004109A MX2023004109A MX2023004109A MX 2023004109 A MX2023004109 A MX 2023004109A MX 2023004109 A MX2023004109 A MX 2023004109A MX 2023004109 A MX2023004109 A MX 2023004109A MX 2023004109 A MX2023004109 A MX 2023004109A
Authority
MX
Mexico
Prior art keywords
oligonucleotides
glial cells
selective delivery
delivering
levels
Prior art date
Application number
MX2023004109A
Other languages
English (en)
Inventor
Maire Jung
Travis Grim
Original Assignee
Dicerna Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dicerna Pharmaceuticals Inc filed Critical Dicerna Pharmaceuticals Inc
Publication of MX2023004109A publication Critical patent/MX2023004109A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening

Abstract

La presente descripción se relaciona con oligonucleótidos para la reducción selectiva del nivel de proteínas y/o de expresión de ARN diana que se expresen en células gliales, y métodos relacionados para administrar tales oligonucleótidos a células gliales.
MX2023004109A 2020-10-08 2021-10-08 Administracion selectiva de oligonucleótidos a células gliales. MX2023004109A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063089406P 2020-10-08 2020-10-08
PCT/US2021/071785 WO2022077024A1 (en) 2020-10-08 2021-10-08 Selective delivery of oligonucleotides to glial cells

Publications (1)

Publication Number Publication Date
MX2023004109A true MX2023004109A (es) 2023-06-28

Family

ID=78536682

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004109A MX2023004109A (es) 2020-10-08 2021-10-08 Administracion selectiva de oligonucleótidos a células gliales.

Country Status (11)

Country Link
EP (1) EP4225919A1 (es)
JP (1) JP2023548658A (es)
KR (1) KR20230104880A (es)
CN (1) CN116761886A (es)
AR (1) AR124275A1 (es)
AU (1) AU2021356639A1 (es)
CA (1) CA3194697A1 (es)
IL (1) IL301940A (es)
MX (1) MX2023004109A (es)
TW (1) TW202228729A (es)
WO (1) WO2022077024A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230374522A1 (en) * 2022-04-15 2023-11-23 Dicerna Pharmaceuticals, Inc. Compositions and methods for modulating scap activity

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003040395A2 (en) 2001-11-07 2003-05-15 Applera Corporation Universal nucleotides for nucleic acid analysis
DE10317389A1 (de) * 2003-04-15 2004-11-04 Dr. Kübler GmbH Synergistisch wirkende Kombination von Phenylbutyrat und Aminobenzoesäure zur Krebstherapie
WO2007030167A1 (en) 2005-09-02 2007-03-15 Nastech Pharmaceutical Company Inc. Modification of double-stranded ribonucleic acid molecules
US20100098664A1 (en) * 2007-11-28 2010-04-22 Mathieu Jean-Francois Desclaux Lentiviral vectors allowing RNAi mediated inhibition of GFAP and vimentin expression
EP3067359A1 (en) 2008-09-23 2016-09-14 Scott G. Petersen Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
WO2013063313A1 (en) 2011-10-25 2013-05-02 Isis Pharmaceuticals, Inc. Antisense modulation of gccr expression
AU2013356383B2 (en) 2012-12-06 2017-08-31 Merck Sharp & Dohme Corp. Disulfide masked prodrug compositions and methods
US20170114341A1 (en) 2014-06-06 2017-04-27 Solstice Biologics, Ltd. Polynucleotide constructs having bioreversible and non-bioreversible groups
EP3865576A1 (en) 2014-12-15 2021-08-18 Dicerna Pharmaceuticals, Inc. Ligand-modified double-stranded nucleic acids
JP7249080B2 (ja) 2016-08-23 2023-03-30 ディセルナ ファーマシューティカルズ インコーポレイテッド 可逆的に修飾されたオリゴヌクレオチドを含む組成物及びその使用
CN110072530A (zh) 2016-09-02 2019-07-30 迪克纳制药公司 4′-磷酸酯类似物和包含其的寡核苷酸
CA3098623A1 (en) * 2018-05-07 2019-11-14 Alnylam Pharmaceuticals, Inc. Extrahepatic delivery

Also Published As

Publication number Publication date
KR20230104880A (ko) 2023-07-11
TW202228729A (zh) 2022-08-01
EP4225919A1 (en) 2023-08-16
AR124275A1 (es) 2023-03-15
WO2022077024A1 (en) 2022-04-14
IL301940A (en) 2023-06-01
CA3194697A1 (en) 2022-04-14
CN116761886A (zh) 2023-09-15
JP2023548658A (ja) 2023-11-20
AU2021356639A1 (en) 2023-05-18

Similar Documents

Publication Publication Date Title
EP2171078A4 (en) ENABLING THE USE OF LONG DSRNA FOR GENE TARGETING IN MAMMALIAN CELLS AND OTHER SELECTED ANIMAL CELLS
NZ750556A (en) Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
PH12018500965A1 (en) Methods and compositions for gene editing in hematopoietic stem cells
WO2006066048A3 (en) Compositions for bacterial mediated gene silencing and methods of using same
EA201790968A1 (ru) Опосредуемая пептидом доставка направляемой рнк эндонуклеазы в клетки
MX2017016088A (es) Oligonucleotidos multi-conjugados definidos.
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
MX2019006510A (es) Sistema y metodos para el biocontrol de patogenos en plantas.
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
WO2016025131A8 (en) Genetic targeting in non-conventional yeast using an rna-guided endonuclease
WO2007087113A3 (en) Natural antisense and non-coding rna transcripts as drug targets
EP2184609A3 (en) Compositions and methods for treating lung cancer
WO2010051533A3 (en) Compositions of engineered human arginases and methods for treating cancer
EP4241854A3 (en) Lysosomal storage disease enzyme
WO2020198509A3 (en) Modified oligonucleotides with increased stability
UA105073C2 (uk) Антитіло проти фракталкіну, композиція і спосіб для лікування запальних порушень
CA3139195A1 (en) Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
WO2018124548A3 (ko) 약물 전달 및 안정화를 위한 복합체 및 그 제조방법
MX2023004109A (es) Administracion selectiva de oligonucleótidos a células gliales.
MX2019015143A (es) Rna guias modificados, complejos crispr-ribonucleoproteina y metodos de uso.
WO2009140701A3 (en) Delivery into cells using ultra-short pulse lasers
WO2008150276A3 (en) Virus coated nanoparticles and uses thereof
AU2019382824A8 (en) Method and means to deliver miRNA to target cells
MX2020013667A (es) Uso de mir-92a o mir-145 en el tratamiento del sindrome de angelman.
WO2021134026A3 (en) Compositions and methods for nucleic acid delivery